Lymphedema Diagnostic market is expected to reach US$ 43.09 Mn. at a CAGR of 3.8% during the forecast period 2029. Lymphedema is a chronic and progressive disorder resulting from impaired lymphatic system function. In developed countries, upper extremity lymphedema is mainly the consequence of breast cancer surgery in which axillary lymph node dissection and radiation alter upper extremity lymphatic flow.To know about the Research Methodology :- Request Free Sample Report Diagnosis of lymphedema is made clinically. Although there is no unique sign or criteria for defining LE, the diagnosis is usually made clinically by a thorough evaluation and physical examination. Family history is important in the diagnosis of primary LE. The main symptoms are chronic swelling, progressive atrophic skin changes, and recurrent infections. It is important to identify whether the swelling is transient or persistent. The lymphedema diagnostics market in developing regions is witnessing a growth in terms of its adoption rate, due to increasing cases of lymphedema, rising prevalence of cancer, and advancement in diagnostic methods. Prevalence estimates for lymphedema are relatively high, yet its prevalence is likely underestimated. Attempts to identify the population impact of lymphedema are hampered by the fact that this chronic, debilitating disease is frequently under-recognized or misdiagnosed. Recent prevalence estimates suggest that chronic edema is present between 1.33 per thousand5 to 1.44 per thousand. The growing prevalence of lymphedema and cancer is a major driver for the market to elevate. Moreover, technological advancements in diagnostic equipment by industries are also expected to boost the market. The increase in advancements is encouraging stakeholders to invest more in the market. Increasing government funds and grants by private organizations are increasing the revenue share of the market. Lymphedema can also be cancer-associated such as lung cancer and breast cancer. The increasing cases of cancer-associated lymphedema are also expected to propel the market. Primary lymphedema is considered to be in around 1.3 children per 10,000 births in North America. Moreover, the population aged over the age of 65 years of age is known to be significantly affected. However, the high cost of diagnostic imaging systems, limited supply of helium, and the short half-life of radiopharmaceuticals are restraining the market growth. The report contains a detailed analysis of the Strengths, Weaknesses, and opportunities of the key players operating in the Global Lymphedema Diagnostic market. It also provides information on current market trends, competitive ranking analysis, regional bifurcation, turnover forecasts, industry drivers, and the key challenges. The report has profiled sixteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques.
Segment Analysis
The Lymphoscintigraphy segment is expected held the largest share of xx% in 2021 and is expected to grow at a CAGR of xx% in the forecast period. Lymphoscintigraphy is a special type of nuclear medicine imaging that provides pictures called scintigrams of the lymphatic system. Nuclear medicine imaging uses small amounts of radioactive material to diagnose, evaluate or treat a variety of diseases. These include many types of cancers, heart disease, gastrointestinal, endocrine, or neurological disorders, and other abnormalities. Because nuclear medicine exams can pinpoint molecular activity, they have the potential to identify disease in its earliest stages. They can also show whether a patient is responding to treatment. Easy reproducibility of this technique is considered to be a major factor driving the market. Also, Lymphoscintigraphy does not directly affect the lymphatic vascular epithelium is a key factor for this segment to elevate. By disease type, cancer is the fastest-growing segment. The increasing prevalence of cancer-associated lymphedema cases is helping the market to grow at a faster pace. Also, awareness about the early diagnosis is associated with market growth. Based on end-users, the hospital segment is accounted for the largest share of the market in 2021. The large share of this segment can be attributed to a large number of lymphedema diagnostic procedures performed in hospitals, the growing adoption of minimum invasive procedures, and the rising adoption of advanced imaging procedures to improve workflow efficiency in hospitals. The Global Lymphedema Diagnostic market is segmented based on-Scope of the Global Lymphedema Diagnostic market : Inquire before buying
Global Lymphedema Diagnostic Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 33.18 Mn. Forecast Period 2023 to 2029 CAGR: 3.8% Market Size in 2029: US $ 43.09 Mn. Segments Covered: by Technology Lymphoscintigraphy X-ray Lymphography Computed Tomography Magnetic Resonance Imaging Fluorescein Sodium Micro lymphangiography Ultrasound Imaging ICG Lymphography Bio impedance Analysis Near-infrared Fluorescence Imaging by End User Hospitals Diagnostic Centers Research and Academic Centers Others by Disease Type Cardiovascular Diseases Cancer Inflammatory Diseases Others Lymphedema Diagnostic market Regional Insights
North America accounted for the largest share of xx% in 2022, the reason being the rising prevalence of cancer-associated lymphedema. Growth in insurance coverage in the U.S. has increased the burden on the country’s healthcare system, which has highlighted the need for improving efficiency and management of work in North America. Well-established healthcare infrastructure, ease of availability is also a key driver affecting the market growth. Investments by key players in this field have boosted the market growth. Rising adoption of technologically advanced diagnostic imaging systems for lymphedema is rapidly growing the market. The Asia Pacific is also expected to witness significant growth during the forecast period due to the increasing geriatric population and rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected to drive the market demand.Key Players operating the Global Lymphedema Diagnostic market
1. Siemens Healthineers 2. GE Healthcare 3. Stryker Corporation 4. Mindray Medical International, Ltd. 5. Philips 6. Canon, Inc 7. Shimazdu Corporation 8. Fluoptics United Imaging Healthcare Co, Ltd 9. Hitachi Ltd 10.Esaote 11.SpA 12.Neusoft Corporation 13.Mindray Medical International Ltd 14.Mitaka, Inc 15.Curadel, LLC 16.ImpediMed Ltd Frequently Asked Questions: 1. Which region has the largest share in Global Lymphedema Diagnostic market? Ans: North America region holds the highest share in 2022. 2. What is the growth rate of Global Lymphedema Diagnosticmarket? Ans: The Global Lymphedema Diagnostic Market is growing at a CAGR of 3.8 % during forecasting period 2023-2029. 3. What is scope of the Global Lymphedema Diagnostic market report? Ans: Global Remote Healthcare Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. What is the study period of this market? Ans: The Global Lymphedema Diagnostic Market is studied from 2022 to 2029.
Global Lymphedema Diagnostic market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: LYMPHEDEMA DIAGNOSTIC Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global LYMPHEDEMA DIAGNOSTIC Market Analysis and Forecast 6.1. LYMPHEDEMA DIAGNOSTIC Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global LYMPHEDEMA DIAGNOSTIC Market Analysis and Forecast, By Technology 7.1. Introduction and Definition 7.2. Key Findings 7.3. LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology 7.4. LYMPHEDEMA DIAGNOSTIC Market Size (US$ Mn) Forecast, By Technology 7.5. LYMPHEDEMA DIAGNOSTIC Market Analysis, By Technology 7.6. LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis, By Technology 8. Global LYMPHEDEMA DIAGNOSTIC Market Analysis and Forecast, By Disease Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type 8.4. LYMPHEDEMA DIAGNOSTIC Market Size (US$ Mn) Forecast, By Disease Type 8.5. LYMPHEDEMA DIAGNOSTIC Market Analysis, By Disease Type 8.6. LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis, By Disease Type 9. Global LYMPHEDEMA DIAGNOSTIC Market Analysis and Forecast By End-user 9.1. Introduction and Definition 9.2. Key Findings 9.3. LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user 9.4. LYMPHEDEMA DIAGNOSTIC Market Size (US$ Mn) Forecast, By End-user 9.5. LYMPHEDEMA DIAGNOSTIC Market Analysis, By End-user 9.6. LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis, By End-user 10. Global LYMPHEDEMA DIAGNOSTIC Market Analysis, By Region 10.1. LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Region 10.2. LYMPHEDEMA DIAGNOSTIC Market Size (US$ Mn) Forecast, By Region 10.3. LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis, By Region 11. North America LYMPHEDEMA DIAGNOSTIC Market Analysis 11.1. Key Findings 11.2. North America LYMPHEDEMA DIAGNOSTIC Market Overview 11.3. North America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology 11.4. North America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 11.4.1. Lymphoscintigraphy 11.4.2. X-ray Lymphography 11.4.3. Computed Tomography 11.4.4. Magnetic Resonance Imaging 11.4.5. Fluorescein Sodium Micro lymphangiography 11.4.6. Ultrasound Imaging 11.4.7. ICG Lymphography 11.4.8. Bio impedance Analysis 11.4.9. Near-infrared Fluorescence Imaging 11.5. North America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type 11.6. North America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 11.6.1. Cardiovascular Diseases 11.6.2. Cancer 11.6.3. Inflammatory Diseases 11.6.4. Others 11.7. North America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user 11.8. North America LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 11.8.1. Hospitals 11.8.2. Diagnostic Centers 11.8.3. Research and Academic Centers 11.8.4. Others 11.9. North America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Country 11.10. North America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Country 11.10.1. U.S. 11.10.2. Canada 11.10.3. Mexico 11.11. North America LYMPHEDEMA DIAGNOSTIC Market Analysis, By Country 11.12. U.S. LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 11.12.1. Lymphoscintigraphy 11.12.2. X-ray Lymphography 11.12.3. Computed Tomography 11.12.4. Magnetic Resonance Imaging 11.12.5. Fluorescein Sodium Micro lymphangiography 11.12.6. Ultrasound Imaging 11.12.7. ICG Lymphography 11.12.8. Bio impedance Analysis 11.12.9. Near-infrared Fluorescence Imaging 11.13. U.S. LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 11.13.1. Cardiovascular Diseases 11.13.2. Cancer 11.13.3. Inflammatory Diseases 11.13.4. Others 11.14. U.S. LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 11.14.1. Hospitals 11.14.2. Diagnostic Centers 11.14.3. Research and Academic Centers 11.14.4. Others 11.15. Canada LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 11.15.1. Lymphoscintigraphy 11.15.2. X-ray Lymphography 11.15.3. Computed Tomography 11.15.4. Magnetic Resonance Imaging 11.15.5. Fluorescein Sodium Micro lymphangiography 11.15.6. Ultrasound Imaging 11.15.7. ICG Lymphography 11.15.8. Bio impedance Analysis 11.15.9. Near-infrared Fluorescence Imaging 11.16. Canada LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 11.16.1. Cardiovascular Diseases 11.16.2. Cancer 11.16.3. Inflammatory Diseases 11.16.4. Others 11.17. Canada LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 11.17.1. Hospitals 11.17.2. Diagnostic Centers 11.17.3. Research and Academic Centers 11.17.4. Others 11.18. Mexico LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 11.18.1. Lymphoscintigraphy 11.18.2. X-ray Lymphography 11.18.3. Computed Tomography 11.18.4. Magnetic Resonance Imaging 11.18.5. Fluorescein Sodium Micro lymphangiography 11.18.6. Ultrasound Imaging 11.18.7. ICG Lymphography 11.18.8. Bio impedance Analysis 11.18.9. Near-infrared Fluorescence Imaging 11.19. Mexico LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 11.19.1. Cardiovascular Diseases 11.19.2. Cancer 11.19.3. Inflammatory Diseases 11.19.4. Others 11.20. Mexico LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 11.20.1. Hospitals 11.20.2. Diagnostic Centers 11.20.3. Research and Academic Centers 11.20.4. Others 11.21. North America LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis 11.21.1. By Technology 11.21.2. By Disease Type 11.21.3. By End-user 11.22. PEST Analysis 11.23. Key Trends 11.24. Key Developments 12. Europe LYMPHEDEMA DIAGNOSTIC Market Analysis 12.1. Key Findings 12.2. Europe LYMPHEDEMA DIAGNOSTIC Market Overview 12.3. Europe LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology 12.4. Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 12.4.1. Lymphoscintigraphy 12.4.2. X-ray Lymphography 12.4.3. Computed Tomography 12.4.4. Magnetic Resonance Imaging 12.4.5. Fluorescein Sodium Micro lymphangiography 12.4.6. Ultrasound Imaging 12.4.7. ICG Lymphography 12.4.8. Bio impedance Analysis 12.4.9. Near-infrared Fluorescence Imaging 12.5. Europe LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type 12.6. Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 12.6.1. Cardiovascular Diseases 12.6.2. Cancer 12.6.3. Inflammatory Diseases 12.6.4. Others 12.7. Europe LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user 12.8. Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 12.8.1. Hospitals 12.8.2. Diagnostic Centers 12.8.3. Research and Academic Centers 12.8.4. Others 12.9. Europe LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Country 12.10. Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Sweden 12.10.7. CIS countries 12.10.8. Rest of Europe 12.11. Germany LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 12.11.1. Lymphoscintigraphy 12.11.2. X-ray Lymphography 12.11.3. Computed Tomography 12.11.4. Magnetic Resonance Imaging 12.11.5. Fluorescein Sodium Micro lymphangiography 12.11.6. Ultrasound Imaging 12.11.7. ICG Lymphography 12.11.8. Bio impedance Analysis 12.11.9. Near-infrared Fluorescence Imaging 12.12. Germany LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 12.12.1. Cardiovascular Diseases 12.12.2. Cancer 12.12.3. Inflammatory Diseases 12.12.4. Others 12.13. Germany LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 12.13.1. Hospitals 12.13.2. Diagnostic Centers 12.13.3. Research and Academic Centers 12.13.4. Others 12.14. U.K. LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 12.14.1. Lymphoscintigraphy 12.14.2. X-ray Lymphography 12.14.3. Computed Tomography 12.14.4. Magnetic Resonance Imaging 12.14.5. Fluorescein Sodium Micro lymphangiography 12.14.6. Ultrasound Imaging 12.14.7. ICG Lymphography 12.14.8. Bio impedance Analysis 12.14.9. Near-infrared Fluorescence Imaging 12.15. U.K. LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 12.15.1. Cardiovascular Diseases 12.15.2. Cancer 12.15.3. Inflammatory Diseases 12.15.4. Others 12.16. U.K. LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 12.16.1. Hospitals 12.16.2. Diagnostic Centers 12.16.3. Research and Academic Centers 12.16.4. Others 12.17. France LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 12.17.1. Lymphoscintigraphy 12.17.2. X-ray Lymphography 12.17.3. Computed Tomography 12.17.4. Magnetic Resonance Imaging 12.17.5. Fluorescein Sodium Micro lymphangiography 12.17.6. Ultrasound Imaging 12.17.7. ICG Lymphography 12.17.8. Bio impedance Analysis 12.17.9. Near-infrared Fluorescence Imaging 12.18. France LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 12.18.1. Cardiovascular Diseases 12.18.2. Cancer 12.18.3. Inflammatory Diseases 12.18.4. Others 12.19. France LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 12.19.1. Hospitals 12.19.2. Diagnostic Centers 12.19.3. Research and Academic Centers 12.19.4. Others 12.20. Italy LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 12.20.1. Lymphoscintigraphy 12.20.2. X-ray Lymphography 12.20.3. Computed Tomography 12.20.4. Magnetic Resonance Imaging 12.20.5. Fluorescein Sodium Micro lymphangiography 12.20.6. Ultrasound Imaging 12.20.7. ICG Lymphography 12.20.8. Bio impedance Analysis 12.20.9. Near-infrared Fluorescence Imaging 12.21. Italy LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 12.21.1. Cardiovascular Diseases 12.21.2. Cancer 12.21.3. Inflammatory Diseases 12.21.4. Others 12.22. Italy LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 12.22.1. Hospitals 12.22.2. Diagnostic Centers 12.22.3. Research and Academic Centers 12.22.4. Others 12.23. Spain LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 12.23.1. Lymphoscintigraphy 12.23.2. X-ray Lymphography 12.23.3. Computed Tomography 12.23.4. Magnetic Resonance Imaging 12.23.5. Fluorescein Sodium Micro lymphangiography 12.23.6. Ultrasound Imaging 12.23.7. ICG Lymphography 12.23.8. Bio impedance Analysis 12.23.9. Near-infrared Fluorescence Imaging 12.24. Spain LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 12.24.1. Cardiovascular Diseases 12.24.2. Cancer 12.24.3. Inflammatory Diseases 12.24.4. Others 12.25. Spain LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 12.25.1. Hospitals 12.25.2. Diagnostic Centers 12.25.3. Research and Academic Centers 12.25.4. Others 12.26. Sweden LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 12.26.1. Lymphoscintigraphy 12.26.2. X-ray Lymphography 12.26.3. Computed Tomography 12.26.4. Magnetic Resonance Imaging 12.26.5. Fluorescein Sodium Micro lymphangiography 12.26.6. Ultrasound Imaging 12.26.7. ICG Lymphography 12.26.8. Bio impedance Analysis 12.26.9. Near-infrared Fluorescence Imaging 12.27. Sweden LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 12.27.1. Cardiovascular Diseases 12.27.2. Cancer 12.27.3. Inflammatory Diseases 12.27.4. Others 12.28. Sweden LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 12.28.1. Hospitals 12.28.2. Diagnostic Centers 12.28.3. Research and Academic Centers 12.28.4. Others 12.29. CIS countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 12.29.1. Lymphoscintigraphy 12.29.2. X-ray Lymphography 12.29.3. Computed Tomography 12.29.4. Magnetic Resonance Imaging 12.29.5. Fluorescein Sodium Micro lymphangiography 12.29.6. Ultrasound Imaging 12.29.7. ICG Lymphography 12.29.8. Bio impedance Analysis 12.29.9. Near-infrared Fluorescence Imaging 12.30. CIS countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 12.30.1. Cardiovascular Diseases 12.30.2. Cancer 12.30.3. Inflammatory Diseases 12.30.4. Others 12.31. CIS countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 12.31.1. Hospitals 12.31.2. Diagnostic Centers 12.31.3. Research and Academic Centers 12.31.4. Others 12.32. Rest of Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 12.32.1. Lymphoscintigraphy 12.32.2. X-ray Lymphography 12.32.3. Computed Tomography 12.32.4. Magnetic Resonance Imaging 12.32.5. Fluorescein Sodium Micro lymphangiography 12.32.6. Ultrasound Imaging 12.32.7. ICG Lymphography 12.32.8. Bio impedance Analysis 12.32.9. Near-infrared Fluorescence Imaging 12.33. Rest of Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 12.33.1. Cardiovascular Diseases 12.33.2. Cancer 12.33.3. Inflammatory Diseases 12.33.4. Others 12.34. Rest of Europe LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 12.34.1. Hospitals 12.34.2. Diagnostic Centers 12.34.3. Research and Academic Centers 12.34.4. Others 12.35. Europe LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis 12.35.1. By Disease Type 12.35.2. By Technology 12.35.3. By End-user 12.36. PEST Analysis 12.37. Key Trends 12.38. Key Developments 13. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Analysis 13.1. Key Findings 13.2. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Overview 13.3. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology 13.4. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 13.4.1. Lymphoscintigraphy 13.4.2. X-ray Lymphography 13.4.3. Computed Tomography 13.4.4. Magnetic Resonance Imaging 13.4.5. Fluorescein Sodium Micro lymphangiography 13.4.6. Ultrasound Imaging 13.4.7. ICG Lymphography 13.4.8. Bio impedance Analysis 13.4.9. Near-infrared Fluorescence Imaging 13.5. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type 13.6. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 13.6.1. Cardiovascular Diseases 13.6.2. Cancer 13.6.3. Inflammatory Diseases 13.6.4. Others 13.7. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user 13.8. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 13.8.1. Hospitals 13.8.2. Diagnostic Centers 13.8.3. Research and Academic Centers 13.8.4. Others 13.9. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Country 13.10. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. ASEAN 13.10.7. Rest of Asia Pacific 13.11. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Analysis, By Country 13.12. China LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 13.12.1. Lymphoscintigraphy 13.12.2. X-ray Lymphography 13.12.3. Computed Tomography 13.12.4. Magnetic Resonance Imaging 13.12.5. Fluorescein Sodium Micro lymphangiography 13.12.6. Ultrasound Imaging 13.12.7. ICG Lymphography 13.12.8. Bio impedance Analysis 13.12.9. Near-infrared Fluorescence Imaging 13.13. China LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 13.13.1. Cardiovascular Diseases 13.13.2. Cancer 13.13.3. Inflammatory Diseases 13.13.4. Others 13.14. China LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 13.14.1. Hospitals 13.14.2. Diagnostic Centers 13.14.3. Research and Academic Centers 13.14.4. Others 13.15. India LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 13.15.1. Lymphoscintigraphy 13.15.2. X-ray Lymphography 13.15.3. Computed Tomography 13.15.4. Magnetic Resonance Imaging 13.15.5. Fluorescein Sodium Micro lymphangiography 13.15.6. Ultrasound Imaging 13.15.7. ICG Lymphography 13.15.8. Bio impedance Analysis 13.15.9. Near-infrared Fluorescence Imaging 13.16. India LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 13.16.1. Cardiovascular Diseases 13.16.2. Cancer 13.16.3. Inflammatory Diseases 13.16.4. Others 13.17. India LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 13.17.1. Hospitals 13.17.2. Diagnostic Centers 13.17.3. Research and Academic Centers 13.17.4. Others 13.18. Japan LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 13.18.1. Lymphoscintigraphy 13.18.2. X-ray Lymphography 13.18.3. Computed Tomography 13.18.4. Magnetic Resonance Imaging 13.18.5. Fluorescein Sodium Micro lymphangiography 13.18.6. Ultrasound Imaging 13.18.7. ICG Lymphography 13.18.8. Bio impedance Analysis 13.18.9. Near-infrared Fluorescence Imaging 13.19. Japan LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 13.19.1. Cardiovascular Diseases 13.19.2. Cancer 13.19.3. Inflammatory Diseases 13.19.4. Others 13.20. Japan LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 13.20.1. Hospitals 13.20.2. Diagnostic Centers 13.20.3. Research and Academic Centers 13.20.4. Others 13.21. South Korea LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 13.21.1. Lymphoscintigraphy 13.21.2. X-ray Lymphography 13.21.3. Computed Tomography 13.21.4. Magnetic Resonance Imaging 13.21.5. Fluorescein Sodium Micro lymphangiography 13.21.6. Ultrasound Imaging 13.21.7. ICG Lymphography 13.21.8. Bio impedance Analysis 13.21.9. Near-infrared Fluorescence Imaging 13.22. South Korea LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 13.22.1. Cardiovascular Diseases 13.22.2. Cancer 13.22.3. Inflammatory Diseases 13.22.4. Others 13.23. South Korea LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 13.23.1. Hospitals 13.23.2. Diagnostic Centers 13.23.3. Research and Academic Centers 13.23.4. Others 13.24. Australia LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 13.24.1. Lymphoscintigraphy 13.24.2. X-ray Lymphography 13.24.3. Computed Tomography 13.24.4. Magnetic Resonance Imaging 13.24.5. Fluorescein Sodium Micro lymphangiography 13.24.6. Ultrasound Imaging 13.24.7. ICG Lymphography 13.24.8. Bio impedance Analysis 13.24.9. Near-infrared Fluorescence Imaging 13.25. Australia LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 13.25.1. Cardiovascular Diseases 13.25.2. Cancer 13.25.3. Inflammatory Diseases 13.25.4. Others 13.26. Australia LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 13.26.1. Hospitals 13.26.2. Diagnostic Centers 13.26.3. Research and Academic Centers 13.26.4. Others 13.27. ASEAN LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 13.27.1. Lymphoscintigraphy 13.27.2. X-ray Lymphography 13.27.3. Computed Tomography 13.27.4. Magnetic Resonance Imaging 13.27.5. Fluorescein Sodium Micro lymphangiography 13.27.6. Ultrasound Imaging 13.27.7. ICG Lymphography 13.27.8. Bio impedance Analysis 13.27.9. Near-infrared Fluorescence Imaging 13.28. ASEAN LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 13.28.1. Cardiovascular Diseases 13.28.2. Cancer 13.28.3. Inflammatory Diseases 13.28.4. Others 13.29. ASEAN LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 13.29.1. Hospitals 13.29.2. Diagnostic Centers 13.29.3. Research and Academic Centers 13.29.4. Others 13.30. Rest of Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 13.30.1. Lymphoscintigraphy 13.30.2. X-ray Lymphography 13.30.3. Computed Tomography 13.30.4. Magnetic Resonance Imaging 13.30.5. Fluorescein Sodium Micro lymphangiography 13.30.6. Ultrasound Imaging 13.30.7. ICG Lymphography 13.30.8. Bio impedance Analysis 13.30.9. Near-infrared Fluorescence Imaging 13.31. Rest of Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 13.31.1. Cardiovascular Diseases 13.31.2. Cancer 13.31.3. Inflammatory Diseases 13.31.4. Others 13.32. Rest of Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 13.32.1. Hospitals 13.32.2. Diagnostic Centers 13.32.3. Research and Academic Centers 13.32.4. Others 13.33. Asia Pacific LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis 13.33.1. By Technology 13.33.2. By Disease Type 13.33.3. By End-user 13.34. PEST Analysis 13.35. Key Trends 13.36. Key Developments 14. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Analysis 14.1. Key Findings 14.2. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Overview 14.3. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology 14.4. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 14.4.1. Lymphoscintigraphy 14.4.2. X-ray Lymphography 14.4.3. Computed Tomography 14.4.4. Magnetic Resonance Imaging 14.4.5. Fluorescein Sodium Micro lymphangiography 14.4.6. Ultrasound Imaging 14.4.7. ICG Lymphography 14.4.8. Bio impedance Analysis 14.4.9. Near-infrared Fluorescence Imaging 14.5. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type 14.6. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 14.6.1. Cardiovascular Diseases 14.6.2. Cancer 14.6.3. Inflammatory Diseases 14.6.4. Others 14.7. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user 14.8. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 14.8.1. Hospitals 14.8.2. Diagnostic Centers 14.8.3. Research and Academic Centers 14.8.4. Others 14.9. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Country 14.10. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.10.5. Rest of Middle East & Africa 14.11. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Analysis, By Country 14.12. GCC Countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 14.12.1. Lymphoscintigraphy 14.12.2. X-ray Lymphography 14.12.3. Computed Tomography 14.12.4. Magnetic Resonance Imaging 14.12.5. Fluorescein Sodium Micro lymphangiography 14.12.6. Ultrasound Imaging 14.12.7. ICG Lymphography 14.12.8. Bio impedance Analysis 14.12.9. Near-infrared Fluorescence Imaging 14.13. GCC Countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 14.13.1. Cardiovascular Diseases 14.13.2. Cancer 14.13.3. Inflammatory Diseases 14.13.4. Others 14.14. GCC Countries LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 14.14.1. Hospitals 14.14.2. Diagnostic Centers 14.14.3. Research and Academic Centers 14.14.4. Others 14.15. South Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 14.15.1. Lymphoscintigraphy 14.15.2. X-ray Lymphography 14.15.3. Computed Tomography 14.15.4. Magnetic Resonance Imaging 14.15.5. Fluorescein Sodium Micro lymphangiography 14.15.6. Ultrasound Imaging 14.15.7. ICG Lymphography 14.15.8. Bio impedance Analysis 14.15.9. Near-infrared Fluorescence Imaging 14.16. South Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 14.16.1. Cardiovascular Diseases 14.16.2. Cancer 14.16.3. Inflammatory Diseases 14.16.4. Others 14.17. South Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 14.17.1. Hospitals 14.17.2. Diagnostic Centers 14.17.3. Research and Academic Centers 14.17.4. Others 14.18. Nigeria LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 14.18.1. Lymphoscintigraphy 14.18.2. X-ray Lymphography 14.18.3. Computed Tomography 14.18.4. Magnetic Resonance Imaging 14.18.5. Fluorescein Sodium Micro lymphangiography 14.18.6. Ultrasound Imaging 14.18.7. ICG Lymphography 14.18.8. Bio impedance Analysis 14.18.9. Near-infrared Fluorescence Imaging 14.19. Nigeria LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 14.19.1. Cardiovascular Diseases 14.19.2. Cancer 14.19.3. Inflammatory Diseases 14.19.4. Others 14.20. Nigeria LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 14.20.1. Hospitals 14.20.2. Diagnostic Centers 14.20.3. Research and Academic Centers 14.20.4. Others 14.21. Egypt LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 14.21.1. Lymphoscintigraphy 14.21.2. X-ray Lymphography 14.21.3. Computed Tomography 14.21.4. Magnetic Resonance Imaging 14.21.5. Fluorescein Sodium Micro lymphangiography 14.21.6. Ultrasound Imaging 14.21.7. ICG Lymphography 14.21.8. Bio impedance Analysis 14.21.9. Near-infrared Fluorescence Imaging 14.22. Egypt LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 14.22.1. Cardiovascular Diseases 14.22.2. Cancer 14.22.3. Inflammatory Diseases 14.22.4. Others 14.23. Egypt LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 14.23.1. Hospitals 14.23.2. Diagnostic Centers 14.23.3. Research and Academic Centers 14.23.4. Others 14.24. Rest of Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 14.24.1. Lymphoscintigraphy 14.24.2. X-ray Lymphography 14.24.3. Computed Tomography 14.24.4. Magnetic Resonance Imaging 14.24.5. Fluorescein Sodium Micro lymphangiography 14.24.6. Ultrasound Imaging 14.24.7. ICG Lymphography 14.24.8. Bio impedance Analysis 14.24.9. Near-infrared Fluorescence Imaging 14.25. Rest of Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 14.25.1. Cardiovascular Diseases 14.25.2. Cancer 14.25.3. Inflammatory Diseases 14.25.4. Others 14.26. Rest of Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 14.26.1. Hospitals 14.26.2. Diagnostic Centers 14.26.3. Research and Academic Centers 14.26.4. Others 14.27. Middle East & Africa LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis 14.27.1. By Technology 14.27.2. By Disease Type 14.27.3. By End-user 14.28. PEST Analysis 14.29. Key Trends 14.30. Key Developments 15. South America LYMPHEDEMA DIAGNOSTIC Market Analysis 15.1. Key Findings 15.2. South America LYMPHEDEMA DIAGNOSTIC Market Overview 15.3. South America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Technology 15.4. South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 15.4.1. Lymphoscintigraphy 15.4.2. X-ray Lymphography 15.4.3. Computed Tomography 15.4.4. Magnetic Resonance Imaging 15.4.5. Fluorescein Sodium Micro lymphangiography 15.4.6. Ultrasound Imaging 15.4.7. ICG Lymphography 15.4.8. Bio impedance Analysis 15.4.9. Near-infrared Fluorescence Imaging 15.5. South America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Disease Type 15.6. South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 15.6.1. Cardiovascular Diseases 15.6.2. Cancer 15.6.3. Inflammatory Diseases 15.6.4. Others 15.7. South America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By End-user 15.8. South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 15.8.1. Hospitals 15.8.2. Diagnostic Centers 15.8.3. Research and Academic Centers 15.8.4. Others 15.9. South America LYMPHEDEMA DIAGNOSTIC Market Value Share Analysis, By Country 15.10. South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Country 15.10.1. Brazil 15.10.2. Colombia 15.10.3. Argentina 15.10.4. Rest of South America 15.11. South America LYMPHEDEMA DIAGNOSTIC Market Analysis, By Country 15.12. Brazil LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 15.12.1. Lymphoscintigraphy 15.12.2. X-ray Lymphography 15.12.3. Computed Tomography 15.12.4. Magnetic Resonance Imaging 15.12.5. Fluorescein Sodium Micro lymphangiography 15.12.6. Ultrasound Imaging 15.12.7. ICG Lymphography 15.12.8. Bio impedance Analysis 15.12.9. Near-infrared Fluorescence Imaging 15.13. Brazil LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 15.13.1. Cardiovascular Diseases 15.13.2. Cancer 15.13.3. Inflammatory Diseases 15.13.4. Others 15.14. Brazil LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 15.14.1. Hospitals 15.14.2. Diagnostic Centers 15.14.3. Research and Academic Centers 15.14.4. Others 15.15. Colombia LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 15.15.1. Lymphoscintigraphy 15.15.2. X-ray Lymphography 15.15.3. Computed Tomography 15.15.4. Magnetic Resonance Imaging 15.15.5. Fluorescein Sodium Micro lymphangiography 15.15.6. Ultrasound Imaging 15.15.7. ICG Lymphography 15.15.8. Bio impedance Analysis 15.15.9. Near-infrared Fluorescence Imaging 15.16. Colombia LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 15.16.1. Cardiovascular Diseases 15.16.2. Cancer 15.16.3. Inflammatory Diseases 15.16.4. Others 15.17. Colombia LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 15.17.1. Hospitals 15.17.2. Diagnostic Centers 15.17.3. Research and Academic Centers 15.17.4. Others 15.18. Argentina LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 15.18.1. Lymphoscintigraphy 15.18.2. X-ray Lymphography 15.18.3. Computed Tomography 15.18.4. Magnetic Resonance Imaging 15.18.5. Fluorescein Sodium Micro lymphangiography 15.18.6. Ultrasound Imaging 15.18.7. ICG Lymphography 15.18.8. Bio impedance Analysis 15.18.9. Near-infrared Fluorescence Imaging 15.19. Argentina LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 15.19.1. Cardiovascular Diseases 15.19.2. Cancer 15.19.3. Inflammatory Diseases 15.19.4. Others 15.20. Argentina LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 15.20.1. Hospitals 15.20.2. Diagnostic Centers 15.20.3. Research and Academic Centers 15.20.4. Others 15.21. Rest of South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Technology 15.21.1. Lymphoscintigraphy 15.21.2. X-ray Lymphography 15.21.3. Computed Tomography 15.21.4. Magnetic Resonance Imaging 15.21.5. Fluorescein Sodium Micro lymphangiography 15.21.6. Ultrasound Imaging 15.21.7. ICG Lymphography 15.21.8. Bio impedance Analysis 15.21.9. Near-infrared Fluorescence Imaging 15.22. Rest of South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By Disease Type 15.22.1. Cardiovascular Diseases 15.22.2. Cancer 15.22.3. Inflammatory Diseases 15.22.4. Others 15.23. Rest of South America LYMPHEDEMA DIAGNOSTIC Market Forecast, By End-user 15.23.1. Hospitals 15.23.2. Diagnostic Centers 15.23.3. Research and Academic Centers 15.23.4. Others 15.24. South America LYMPHEDEMA DIAGNOSTIC Market Attractiveness Analysis 15.24.1. By Technology 15.24.2. By Disease Type 15.24.3. By End-user 15.25. PEST Analysis 15.26. Key Trends 15.27. Key Developments 16. Company Profiles 16.1. Market Share Analysis, By Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players By price, presence, market share, Disease Type, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A By Regions, Investment and Disease Type 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Siemens Healthineers 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. GE Healthcare 16.3.3. Stryker Corporation 16.3.4. Mindray Medical International, Ltd. 16.3.5. Philips 16.3.6. Canon, Inc 16.3.7. Shimazdu Corporation 16.3.8. Fluoptics United Imaging Healthcare Co, Ltd 16.3.9. Hitachi Ltd 16.3.10. Esaote 16.3.11. SpA 16.3.12. Neusoft Corporation 16.3.13. Mindray Medical International Ltd 16.3.14. Mitaka, Inc 16.3.15. Curadel, LLC 16.3.16. ImpediMed Ltd 16.3.17. Others